A preclinical study of a novel dual-modality contrast agent in rodent models.

Front Bioeng Biotechnol · 2025 · PMC11966174 · PMID 40182986

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

After 0.5 h, the CNR in the PL002 group showed a trend of increasing with higher doses.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.